Cardiac safety in cluster headache patients using the very high dose of verapamil (≥720 mg/day)

M Lanteri-Minet, F Silhol, V Piano, A Donnet, M Lanteri-Minet, F Silhol, V Piano, A Donnet

Abstract

Use of high doses of verapamil in preventive treatment of cluster headache (CH) is limited by cardiac toxicity. We systematically assess the cardiac safety of the very high dose of verapamil (verapamil VHD) in CH patients. Our work was a study performed in two French headache centers (Marseilles-Nice) from 12/2005 to 12/2008. CH patients treated with verapamil VHD (≥720 mg) were considered with a systematic electrocardiogram (EKG) monitoring. Among 200 CH patients, 29 (14.8%) used verapamil VHD (877±227 mg/day). Incidence of EKG changes was 38% (11/29). Seven (24%) patients presented bradycardia considered as nonserious adverse event (NSAE) and four (14%) patients presented arrhythmia (heart block) considered as serious adverse event (SAE). Patients with EKG changes (1,003±295 mg/day) were taking higher doses than those without EKG changes (800±143 mg/day), but doses were similar in patients with SAE (990±316 mg/day) and those with NSAE (1,011±309 mg/day). Around three-quarters (8/11) of patients presented a delayed-onset cardiac adverse event (delay ≥2 years). Our work confirms the need for systematic EKG monitoring in CH patients treated with verapamil. Such cardiac safety assessment must be continued even for patients using VHD without any adverse event for a long time.

© The Author(s) 2011. This article is published with open access at Springerlink.com

References

    1. Edlund W, Gronseth G, So Y, Franklin G (2004) Clinical practice guideline process manual. American Academy of Neurology, St. Paul, pp 1–57
    1. Francis GJ, Becker WJ, Pringshiem TM. Acute and preventive pharmacologic treatment of cluster headache. Neurology. 2010;75:463–473. doi: 10.1212/WNL.0b013e3181eb58c8.
    1. May A, Leone M, Afra J, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol. 2006;13:1066–1077. doi: 10.1111/j.1468-1331.2006.01566.x.
    1. Bussone G, Leone M, Peccarisi C, et al. Double blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache. 1990;30:411–417. doi: 10.1111/j.1526-4610.1990.hed3007411.x.
    1. Leone M, D’Amico D, Frediani F, Moschiano F, Grazzi L, Attanasio A. Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. Neurology. 2000;54:1382–1385.
    1. Gabai IJ, Speirings ELH. Prophylactic treatment of cluster headache with verapamil. Headache. 1989;29:167–168. doi: 10.1111/j.1526-4610.1989.hed2903167.x.
    1. Tflelt-Hansen P, Tfelt-Hansen J. Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2008;49:117–125. doi: 10.1111/j.1526-4610.2008.01298.x.
    1. Luurtsema G, Molthoff CF, Windhorst AD, et al. (R)- and (S)[11C]verapamil as PET-tracers for measuring P-glycioprotein function: in vitro and in vivo evaluation. Nucl Med Biol. 2003;30:747–751. doi: 10.1016/S0969-8051(03)00078-7.
    1. Cohen AS, Matharu MS, Goadsby PJ. Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology. 2007;69:668–675. doi: 10.1212/01.wnl.0000267319.18123.d3.
    1. Lanteri-Minet M, Autret A, Baudesson G, et al. French survey network on headaches and facial pains. In: Olesen J, et al., editors. The classification and diagnosis of headache disorders. New York: Oxford University Press; 2005. pp. 287–293.
    1. Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders, 2nd edn. Cephalalgia 24(Suppl 1):1–160
    1. Beitelsheess AL, Gong Y, Wang D, et al. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the International VErapamil SR/Trandolapril Study (INVSET) Pharmacogenetic Genomics. 2007;17:719–729. doi: 10.1097/FPC.0b013e32810f2e3c.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe